李红良 - 武汉大学 - 基础医学院

个人简介

教育经历 2002-2005 北京协和医科大学，生物化学与分子生物学，博士 1999-2002 暨南大学，药理学，硕士 1994-1999 广东医科大学，临床医学，学士工作经历 2017-今武汉大学基础医学院，院长 2016-今武汉大学模式动物研究所，所长 2015-今武汉大学动物实验中心/A3实验室，主任 2008-今武汉大学人民医院心血管内科，教授、博士生导师 2008-今武汉大学人民医院心血管病研究所，副所长 2006-2008 加拿大多伦多大学，博士后 2006-2006 美国哈佛大学医学院，博士后

研究领域

心脑血管代谢性疾病的发生机制和防治，基因工程动物模型的研发

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Wang ZH, Zhang XJ, Zhang P, Wang XH, Chen I, Gao C, Deng KQ, Gong J, Yokota T, Wang H, Cass A, Ren SX, Vondriska T, Li GP, Yang HT, Xiao XS,Li H*,Wang Y*, A long non- coding RNA defines an epigenetic check point for cardiac hypertrophy.Nat Med. 2016 ,22(10):1131-1139. Wang P, Zhang X, Luo P, Jiang X, Zhang P, Guo J, Zhao G, Zhu X, Zhang Y, Yang S andLi H*. Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling.Nat Commun. 2016; 7：10592. Ji Y, Zhang P, Zhang X, Zhao Y, Deng K, Jiang X, Wang P, Huang Z andLi H*. The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.Nat Commun. 2016; 7：11267. Deng K, Wang A, Ji Y, Zhang X, Fang J, Zhang Y, Zhang P, Jiang X, Gao L, Zhu X, Zhao Y, Gao L, Yang Q, Zhu X, Wei X, Pu J*andLi H*. Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy.Nat Commun. 2016; 7：11432. Zhang S, Zhu L, Chen H, Zhang R, Zhang P, Jiang D, Gao L, Tian S, Wang L, Zhang Y, Wang P, Zhang X, Zhang X, Liu D andLi H*. Interferon regulatory factor 9 is critical for neointima formation following vascular injury.Nat Commun. 2014; 5：5160. Lu Y, Li Z, Jiang D, Wang L, Zhang Y, Chen K, Zhang X, Liu Y, Fan G, Chen Y, Yang Q, Zhou Y, Zhang X, Liu D andLi H*. TRAF1 is a critical regulator of cerebral ischaemia–reperfusion injury and neuronal death.Nat Commun. 2013; 4：2852. Xiang M, Wang P, Wang A, Zhang X, Zhang Y, Zhang P, Mei F, Chen M* andLi H*. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.J Hepatol. 2016; 64：1365-1377. Hu J, Zhu X, Zhang X, Wang P, Zhang R, Zhang P, Zhao G, Gao L, Zhang X, Tian S andLi H*. Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury.J Hepatol. 2016; 64：146-159. Gao L, Wang P, Zhang Y, Yu C, Ji Y, Wang X, Zhang P, Jiang X, Jin H, Huang Z, Zhang Z* andLi H*. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.J Hepatol. 2016;65:125-36. Wang P, Zhang R, Huang L, Zhu L, Jiang D, Chen H, Zhang Y, Tian S, Zhang X, Zhang X, Liu D andLi H*. Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury.J Hepatol. 2015; 62：111-120. Wang P, Zhang X andLi H*. Liver capsule: IRFs in hepatocytes: Pathophysiology.Hepatology. 2016; 63：1706. Wang X, Zhang R, She Z, Zhang X, Jiang D, Wang T, Gao L, Deng W, Zhang S, Zhu L, Guo S, Chen K, Zhang X, Liu D andLi H*. Interferon regulatory factor 3 constrains IKKβ/NF-κB signaling to alleviate hepatic steatosis and insulin resistance.Hepatology. 2014; 59：870-885. Wang X, Zhang R, Jiang D, Deng W, Zhang S, Deng S, Zhong J, Wang T, Zhu L, Yang L, Hong S, Guo S, Chen K, Zhang X, She Z, Chen Y, Yang Q, Zhang X andLi H*. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice.Hepatology. 2013; 58：603-616. Zhang X, Zhang P andLi H*. Interferon Regulatory Factor Signalings in Cardiometabolic Diseases.Hypertension. 2015; 66：222-247. Jiang X, Deng K, Luo Y, Jiang D, Gao L, Zhang X, Zhang P, Zhao G, Zhu X andLi H*. Tumor necrosis factor receptor-associated factor 3 is a positive regulator of pathological cardiac hypertrophyHypertension. 2015; 66：356-367. Guo S, Li ZZ, Gong J, Xiang M, Zhang P, Zhao GN, Li M, Zheng A, Zhu X, Lei H, Minoru T andLi H*. Oncostatin M Confers Neuroprotection against Ischemic Stroke.J Neurosci. 2015; 35：12047-12062.